Breakthrough for 800 Million Patients? Kidney Disease Drug Shows Powerful New Benefits
The drug cut major kidney and cardiovascular risks, and more than half of treated patients saw at least a 30% drop in urine protein.
4 Articles
4 Articles
Breakthrough for 800 Million Patients? Kidney Disease Drug Shows Powerful New Benefits
New findings indicate that finerenone may help protect kidney function and reduce major health risks in people with chronic kidney disease who do not have diabetes. Chronic kidney disease affects an estimated 800 million people worldwide and is one of the leading causes of kidney failure, cardiovascular complications, and premature death. Yet for many patients [...]
Finerenone Kidney Drug Shown to Protect Heart and Kidneys in Millions More Patients After Three Major 2026 Studies
Three major studies published in NEJM, JAMA, and The Lancet in June 2026 show finerenone protects kidneys and hearts in non-diabetic CKD patients, expanding its potential reach to millions.
A recent study conducted by Hiddo Lambers Heerspink of the University Medical Center Groningen reveals that finerenone, a drug previously associated with the treatment of diabetic kidney disease, may also offer significant benefits to patients with chronic kidney disease (CKD) who do not have diabetes. Research reveals new benefits of finerenone. The new findings indicate that finerenone may protect kidney function and reduce health risks in peo…
Groningen and Sydney – The non-steroidal, and therefore better-tolerated, aldosterone antagonist finerenone can also slow the progression of chronic kidney disease in non-diabetics. This is shown by the results of a phase 3 study presented at the European Renal Association Congress in Glasgow and published in the New England Journal of Medicine...
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
